HELIX BIOPHARMA CORP (HBP.CA) Fundamental Analysis & Valuation

TSX:HBP • CA4229102088

Current stock price

1.8 CAD
-0.06 (-3.23%)
Last:

This HBP.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. HBP.CA Profitability Analysis

1.1 Basic Checks

  • HBP had negative earnings in the past year.
  • HBP had a negative operating cash flow in the past year.
  • In the past 5 years HBP always reported negative net income.
  • HBP had a negative operating cash flow in each of the past 5 years.
HBP.CA Yearly Net Income VS EBIT VS OCF VS FCFHBP.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2M -4M -6M -8M -10M

1.2 Ratios

  • HBP's Return On Assets of -25.58% is fine compared to the rest of the industry. HBP outperforms 70.83% of its industry peers.
  • HBP has a better Return On Equity (-30.36%) than 75.00% of its industry peers.
Industry RankSector Rank
ROA -25.58%
ROE -30.36%
ROIC N/A
ROA(3y)-420.37%
ROA(5y)-326.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HBP.CA Yearly ROA, ROE, ROICHBP.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20K 40K 60K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for HBP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HBP.CA Yearly Profit, Operating, Gross MarginsHBP.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. HBP.CA Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, HBP has more shares outstanding
  • The number of shares outstanding for HBP has been reduced compared to 5 years ago.
  • HBP has a worse debt/assets ratio than last year.
HBP.CA Yearly Shares OutstandingHBP.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
HBP.CA Yearly Total Debt VS Total AssetsHBP.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M

2.2 Solvency

  • An Altman-Z score of 10.89 indicates that HBP is not in any danger for bankruptcy at the moment.
  • HBP has a Altman-Z score of 10.89. This is amongst the best in the industry. HBP outperforms 91.67% of its industry peers.
  • A Debt/Equity ratio of 0.02 indicates that HBP is not too dependend on debt financing.
  • HBP's Debt to Equity ratio of 0.02 is amongst the best of the industry. HBP outperforms 83.33% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 10.89
ROIC/WACCN/A
WACCN/A
HBP.CA Yearly LT Debt VS Equity VS FCFHBP.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M 10M -10M 15M

2.3 Liquidity

  • HBP has a Current Ratio of 0.23. This is a bad value and indicates that HBP is not financially healthy enough and could expect problems in meeting its short term obligations.
  • HBP has a Current ratio (0.23) which is comparable to the rest of the industry.
  • A Quick Ratio of 0.23 indicates that HBP may have some problems paying its short term obligations.
  • HBP has a Quick ratio (0.23) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 0.23
Quick Ratio 0.23
HBP.CA Yearly Current Assets VS Current LiabilitesHBP.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. HBP.CA Growth Analysis

3.1 Past

  • HBP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.84%, which is quite impressive.
EPS 1Y (TTM)56.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.28%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HBP.CA Yearly EPS VS EstimatesHBP.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 -0.1 -0.2 -0.3

More info and screens

Find the best growth stocksShow best growing peers

0

4. HBP.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • HBP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HBP.CA Price Earnings VS Forward Price EarningsHBP.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HBP.CA Per share dataHBP.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05 0.1 0.15 0.2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. HBP.CA Dividend Analysis

5.1 Amount

  • HBP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HBP.CA Fundamentals: All Metrics, Ratios and Statistics

HELIX BIOPHARMA CORP

TSX:HBP (4/1/2026, 7:00:00 PM)

1.8

-0.06 (-3.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)06-15
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners8.6%
Ins Owner ChangeN/A
Market Cap137.48M
Revenue(TTM)N/A
Net Income(TTM)-4.88M
Analysts80
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.56
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.08
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0
BVpS0.21
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -25.58%
ROE -30.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-420.37%
ROA(5y)-326.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.23
Quick Ratio 0.23
Altman-Z 10.89
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)65.64%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.28%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y50.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y29.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.75%
OCF growth 3YN/A
OCF growth 5YN/A

HELIX BIOPHARMA CORP / HBP.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of HELIX BIOPHARMA CORP (HBP.CA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to HBP.CA.


What is the valuation status for HBP stock?

ChartMill assigns a valuation rating of 0 / 10 to HELIX BIOPHARMA CORP (HBP.CA). This can be considered as Overvalued.


How profitable is HELIX BIOPHARMA CORP (HBP.CA) stock?

HELIX BIOPHARMA CORP (HBP.CA) has a profitability rating of 1 / 10.


How financially healthy is HELIX BIOPHARMA CORP?

The financial health rating of HELIX BIOPHARMA CORP (HBP.CA) is 4 / 10.